Access to anti-obesity drugs like Ozempic and Wegovy is presenting challenges for individuals from historically underrepresented populations, despite the materially higher prevalence of diabetes and obesity among this demographic. Concerns are growing as these medications gain popularity for their weight loss and other benefits, with disparities in prescription rates, affordability, and even knowledge of the drugs’ existence creating an “access divide” across population segments.
White individuals, with a historically lower diabetes prevalence, are four times more likely than Black individuals to receive prescriptions for semaglutide, the anti-obesity and diabetes medication, according to a CNN/Epic Research report. This inequity is attributed largely to economic factors, where financial considerations play a significant role in medication distribution.
The study found that, despite eligibility, Black and Hispanic individuals face barriers, such as lack of insurance and lower income levels, affecting access to these medications. Additionally, out-of-pocket costs pose a challenge, with Medicaid coverage varying by state.
To address these issues, health equity proponents have been advocating to raise awareness and urging that discounted programs become more widely accessible, and that doctors prioritize prescriptions based on need. Educating clinicians on health inequities and advocating for diversity in medical advertising are additional steps they recommend towards improving access and reducing health disparities in this area.
